OverviewSuggest Edit

Definigen is a company that provides functional disease model human cells, including hepatocytes, pancreatic beta cells, and intestinal organoids. It develops OptiDIFF, a platform technology that focuses on induced pluripotent stem cell (iPSC) generation, CRISPR-Cas9 gene editing, iPSC differentiation, and custom disease model development. The company delivers its services across life science, drug discovery, and regenerative medicine sectors.
TypePrivate
Founded2012
HQBabraham, GB
Websitedefinigen.com

Latest Updates

Employees (est.) (May 2022)19(-5%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Definigen

Ben Cons

Ben Cons

Chairman
Marcus Yeo

Marcus Yeo

Chief Executive Officer
Richard Willock

Richard Willock

Chief Business Officer
Marek Gumienny

Marek Gumienny

Non-Executive Director
Ludovic Vallier

Ludovic Vallier

Chief Scientific Officer
Chris Kirton

Chris Kirton

Chief Operating Officer
Show more

Definigen Office Locations

Definigen has an office in Babraham
Babraham, GB (HQ)
Babraham Research Campus Moneta Building B280
Show all (1)

Definigen Financials and Metrics

Summary Metrics

Founding Date

2012

Definigen total Funding

$9.1 m

Definigen latest funding size

$886.77 k

Time since last funding

4 years ago

Definigen investors

Definigen's latest funding round in November 2018 was reported to be $886.8 k. In total, Definigen has raised $9.1 m
Show all financial metrics

Definigen Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Definigen Online and Social Media Presence

Embed Graph

Definigen Blogs

DefiniGEN appoints Dr Chris Kirton as Chief Executive Officer

Cambridge, UK – Thursday 20th January 2022 – DefiniGEN is pleased to announce the appointment of Dr Chris Kirton as Chief Executive Officer. Chris has more than 16 years of operational experience and joined DefiniGEN as Chief Operating Officer in June 2020. The appointment is key for DefiniGEN a…

DefiniGEN Achieves ISO 9001: (2015) Certification

Cambridge July 29th, 2021: DefiniGEN, a provider of iPSC-derived products and disease modelling services, today announces that the company has earned ISO 9001: 2015 certification at its Cambridge UK facility. ISO certification confirms excellence in quality management standards and validates the com…

DefiniGEN appoints Dr Ben Cons as Chairman of its Board

Cambridge, UK- 29 April 2021: DefiniGEN, the world leader in human induced pluripotent stem cell (iPSC) differentiation and disease modelling, today announces the appointment of Dr Ben Cons as Chairman of the Board. A respected entrepreneur and pharmaceutical and healthcare leader, he has a prov…

DefiniGEN Secures £3.25 million in Funding to Fast-Track Growth

19th November 2020, Cambridge: DefiniGEN – a provider of human cell products and services – has closed a £3.25 million funding round to accelerate its next phase of growth. This includes £2 million from BGF, the UK’s most active investor, alongside its existing consortium of investors led by 24Hayma…

Definigen Frequently Asked Questions

  • When was Definigen founded?

    Definigen was founded in 2012.

  • Who are Definigen key executives?

    Definigen's key executives are Ben Cons, Marcus Yeo and Richard Willock.

  • How many employees does Definigen have?

    Definigen has 19 employees.

  • Who are Definigen competitors?

    Competitors of Definigen include SUN bioscience, Creyon Bio and Nuclera.

  • Where is Definigen headquarters?

    Definigen headquarters is located at Babraham Research Campus Moneta Building B280, Babraham.

  • Where are Definigen offices?

    Definigen has an office in Babraham.

  • How many offices does Definigen have?

    Definigen has 1 office.